Implandata Ophthalmic Products GmbH
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Implandata Ophthalmic Products GmbH
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Only 10 approvals from outside the US were recorded in May in Medtech Insight's approvals tracker. Half of those were for in vitro diagnostics, including three for companion diagnostic for cancer drugs.
This article was adapted from "In Glaucoma, Devices Go Eye-to-Eye with Drugs," in the September 2010 issue of Start-Up.
Glaucoma is of serious interest to VCs and strategic investors because of its sheer size; the disease affects 3 million people, most of them managed by drugs. Glaucoma drugs have created a $4 billion market, but have several problems, the greatest of which is non-compliance. Glaukos and other device companies aim to introduce devices that are safe and efficacious enough to compete directly with drugs, rather than standing in as an alternative to today's glaucoma surgeries reserved for end-stage patients. Glaukos recently marked a first of its kind victory; with a tiny implantable ophthalmic stent, Glaukos emerged from a PMA clinical trial that convinced an FDA panel of the benefit-to-risk ratio of its approach when used as a first-line therapy in a select group.
- Diagnostic Equipment & Supplies
- Implantable Devices
- Monitoring Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.